Form 4: Apellis CTO Sells Shares for Tax Obligations

Apellis Pharmaceuticals' Chief Technical Officer, Nur Nicholson, sold 2,618 shares of common stock to cover tax withholding related to restricted stock unit release.

Summary

• Nur Nicholson, Chief Technical Officer of Apellis Pharmaceuticals, Inc., reported a transaction involving company stock.
• On January 13, 2026, Nicholson sold 2,618 shares of Apellis Common Stock.
• The shares were sold at a price of $22.1872 per share.
• The purpose of this sale was to cover tax withholding obligations associated with Restricted Stock Units that were released on January 12, 2026.
• Following this transaction, Nicholson beneficially owns 81,046 shares of Common Stock.

Sentiment

Score: 5

Explanation: Neutral. This is a routine, non-discretionary sale to cover tax obligations upon the vesting of restricted stock units, which is a common occurrence for executives and does not typically reflect a change in sentiment towards the company's prospects.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it primarily reports an individual insider transaction.

Industry Context

This transaction is a routine insider stock sale to cover tax obligations upon the vesting of restricted stock units, a common practice for executives receiving equity compensation across various industries. It does not reflect broader industry trends or competitive dynamics.

Related Party Transactions

• The reported transaction is an insider sale of common stock by Nur Nicholson, Chief Technical Officer, to cover tax withholding on Restricted Stock Units.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, non-discretionary sale for tax purposes, not indicative of a change in company fundamentals or insider confidence.
• Employees: No direct impact on the broader employee base.

Key Dates

Recommendation

The transaction reported is a routine sale of shares by an executive to cover tax withholding obligations upon the vesting of Restricted Stock Units. This is a common and expected event and does not typically signal a change in the company's fundamental outlook or the executive's confidence. Therefore, it provides no new information to warrant a change in investment recommendation based solely on this filing.

Keywords

Apellis Pharmaceuticals, APLS, Nur Nicholson, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, Tax Withholding, Officer Transaction